L. Santarpia, A. K. El-Naggar, G. J. Cote, J. N. Myers and S. I. Sherman, “Phosphatidylinositol 3-kinase/akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer,” Journal of Clinical Endocrinology & Metabolism, Vol. 93, No. 1, 2008, pp. 278-284. doi:10.1210/jc.2007-1076

has been cited by the following article:

• TITLE: Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer

  AUTHORS: Kenneth M. Wong, Theodore Scott Nowicki, Carmelo Puccio, Tauseef Ahmed, Raj Tiwari, Jan Geliebter, Augustine Moscatello

  KEYWORDS: Sunitinib; Anaplastic Thyroid Cancer; Tyrosine Kinase Inhibitor; Chemotherapy; ATC

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.2, April 24, 2012

  ABSTRACT: Background: Anaplastic thyroid cancer (ATC), while rare, carries a uniformly poor prognosis. Current treatment includes surgery when possible, radiotherapy, and chemotherapy. Multiple chemotherapeutic agents are in the process of clinical testing, and promising agents include those in the tyrosine kinase inhibitor family. Our patient represents a novel case of ATC treated with sunitinib, one such tyrosine kinase inhibitor. Methods/Results: We utilized the experimental sunitinib in conjunction with radiation therapy to treat a patient with aggressive ATC in whom curative resection was unable to be achieved due to carotid sheath and tracheal involvement. The patient had marked clinical response and sustained stable disease for 8 months, which coincides with reported data regarding sunitinib to treat other thyroid malignancies. Conclusion: Our case illustrates the efficacy of sunitinib therapy as a possible adjunct in the treatment of ATC.